ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

News

Oct. 5, 2023 ADmit therapeutics closes a €5.4 million funding round led by Clave Capital, through its Clave Innohealth f.c.r. fund The European Innovation Council (EIC) Fund and the Alzheimer's Drug Discovery Foundation Diagnostic Accelerator join the round

ADmit has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator (DxA), alongside other investors such as Lavanda Ventures, Ship2B and WA4Steam. This funding round will enable the company to obtain CE marking and FDA approval for the commercialization of MAP-AD in Europe and the United States.

MAP-AD, the technology, is based on an algorithm capable of stratifying Mild Cognitive Impairment (MCI) patients based on their probability of progressing to AD dementia (ADD) through the epigenetic analysis of mitochondrial DNA (mtDNA) methylation signatures in a patient's blood sample. The innovative approach of MAP-AD lies in these disruptive findings, a combination of patented biomarkers based on mtDNA methylation patterns and a novel algorithm to link the pattern with the clinical prognosis of ADD.

The use of MAP-AD technology by pharmaceutical companies to optimize patient selection has the potential to reduce the time and costs associated with clinical trials, increasing the likelihood of identifying new effective therapies for AD.

There is a clear need for individualized prognosis of MCI progression to ADD. Timely and accurate diagnosis of AD impacts the quality of life of patients and their families by allowing for timely and optimized treatment.

Marta Barrachina, CEO of ADmit, highlighted: "Our unique value proposition allows us to calculate the probability of a patient with MCI progressing to AD with just a blood sample and using state-of-the-art sequencing techniques. This enables clinicians to optimally stratify patients and prescribe the best treatment."

From Clave, "we highly value the results achieved to date, the diagnostic capability in very early stages of neurodegenerative diseases such as Alzheimer's and others, in a highly prevalent and growing market where innovative therapies are emerging," said Santiago Lozano, Director of Funds and Clave Innohealth f.c.r. Giacomo de Simone, a board member at Clave, particularly appreciates the scientific capabilities of the team led by Marta and the disruptive potential that this technology could have in the clinical field.

Feb. 27, 2023 ADmit Therapeutics announces a new investment of up to $1,886,058 from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation.

The investment represents a continuation of the Diagnostics Accelerator’s support for the clinical validation and regulatory approval of our breakthrough technology based on novel biomarkers related to mitochondrial DNA. Mitochondrial DNA is the circular chromosome found inside mitochondria, which are responsible for energy production within cells. DNA methylation, a chemical modification where a methyl group is added to the DNA, plays an important role in regulating gene expression. DNA methylation changes are associated with a number of diseases, including Alzheimer’s disease. ADmit is developing a test using next-generation sequencing and a machine learning approach to measure methylation changes in mitochondrial DNA that can predict the progression to Alzheimer’s disease dementia from Mild Cognitive Impairment. Employing this technology for clinical trial screening and patient enrollment has the potential to reduce timelines and costs associated with clinical trials, boosting opportunities for the identification of new and effective drugs.

The Diagnostics Accelerator, created in July 2018, is a partnership of funders with commitments totaling $100 million to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. In the initiative's newly launched second phase, the NFL Players Association (NFLPA), Eli Lilly & Company, Biogen and the Shanahan Family Foundation added their support to that of initial partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos and MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, and The Association for Frontotemporal Degeneration, among others.

The Diagnostics Accelerator is dedicated to advancing the development of low cost, minimally invasive, scalable biomarkers and diagnostic tests for Alzheimer's disease and related dementias. Through translational research awards and access to consulting support from industry experts, this program focuses on accelerating innovation in both academia and industry towards the development of novel peripheral and digital biomarkers for Alzheimer’s. To learn more about the initiative, visit the website at www.alzdiscovery.org/accelerator.

Nov. 29, 2022 ADmit will present the AD classifier model at the 15th annual CTAD conference in San Francisco

ADmit is pleased to announce that data of the AD classifier model will be presented for the first time by Dr. Marta Blanch at the 15th annual CTAD conference taking place the next November 29 - December 2 in San Francisco.




ADmit will present the AD classifier model at the 15th annual CTAD conference in San Francisco
Nov. 28, 2022 ADmit is invited to participate in the DxA's investigator Meeting organized by the Alzheimer's Drug Discovery Foundation

This event brings together portfolio members and partners to present their funded work and discuss the current state of biomarkers for Alzheimer’s Disease and related dementias. Marta Blanch will present our diagnostic platform.




ADmit is invited to participate in the DxA's investigator Meeting organized by the Alzheimer's Drug Discovery Foundation
June 15, 2022 ADmit Therapeutics selected for the Company Presentation at the BIO International Convention 2022

ADmit Therapeutics attends the BIO International Convention, the world's largest gathering of leaders in the biotech and life sciences industries the 13-16 June in San Diego (US). In addition, our project was selected for the Company Presentation section. The company was hosted by the European Pavilion as it was one of the 20 european SMEs selected by the EIC Overseas Trade Fairs Programme.

 




ADmit Therapeutics selected for the Company Presentation at the BIO International Convention 2022
Nov. 25, 2021 Our CEO is a new member in the Scientific Review Board at the Alzheimer's Drug Discovery Foundation

Marta Barrachina, CEO and Co-Founder of our company is a new member in the Scientific Review Board at the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998, the ADDF is the only nonprofit dedicated solely to developing drugs and diagnostics for the treatment and prevention of Alzheimer’s disease and related dementias, including frontotemporal, vascular, and Lewy body dementias.

https://www.alzdiscovery.org/about-addf/board-scientific

 

Nov. 4, 2021 Our CEO receives the FIDEM 2021 Innovació Award

The International Foundation of Women Entrepreneurs (FIDEM) awards our CEO, Marta Barrachina with the FIDEM 2021 Innovation award. The ceremony was held in the CosmoCaixa of Barcelona.




Our CEO receives the FIDEM 2021 Innovació Award
Oct. 27, 2021 ADmit Therapeutics is supported again by the Spanish Ministerio de Ciencia e Innvocación (MICINN)

Paula Ferrer is our first industrial PhD candidate co-financed by the "Dcotorados Industriales-2020" program from the MICINN




ADmit Therapeutics is supported again by the Spanish Ministerio de Ciencia e Innvocación (MICINN)
Oct. 11, 2021 ADmit Therapeutics will attend the second Diagnostics Accelerator Investigators' Meeting organized by the ADDF

Dr. Marta Barrachina and Dr. Marta Blanch will discuss their results in the Session II, Part 1, Peripheral Molecular Biomarkers of ADRD (October 12, 2021)


meetings.alzdiscovery.org/dxa/
July 11, 2021 The catalan press El Punt Avui+ promotes awareness of our company
Aug. 24, 2020 ADmit Therapeutics receives an important investment from the European Innovation Council

ADmit Therapeutics is a winner of the EIC Accelerator in its first application. It will receive up to €3.33M among grant and additional equity financing from EIC Fund. This support from the European Commission will allow the commercialization of the first early Alzheimer's diagnostic test in blood samples.




ADmit Therapeutics receives an important investment from the European Innovation Council
May 8, 2020 ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test

ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias, and  advance the development of more targeted treatments. 

ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), located in Barcelona, which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.




ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test
Apr. 2, 2020 ADmit Therapeutics has been certified as an Innovative SME



ADmit Therapeutics has been certified as an Innovative SME
Nov. 11, 2019 ADmit Therapeutics is supported with a Neotec granted by the CDTI

An important grant from the CDTI (Ministerio de Ciencia e Innovación) for our development plan along 2020.




ADmit Therapeutics is supported with a Neotec granted by the CDTI
Oct. 11, 2019 ADmit Therapeutics is granted by the EIT Health Digital Sandbox programme

This grant will allow us to get access to Scandinavian Biobanks




ADmit Therapeutics is granted by the EIT Health Digital Sandbox programme
Sept. 20, 2019 We have been granted with a Torres Quevedo Contract

Congratulations to our postdoc Marta Blanch!




We have been granted with a Torres Quevedo Contract
June 27, 2018 DemoDay at La Salle Technova

We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates.

https://twitter.com...

June 20, 2018 Investment Forum from ACCIÓ 2018

Finalists in the Investment Forum from ACCIÓ 2018!

http://www.accio.gencat.cat...




Investment Forum from ACCIÓ 2018
May 15, 2018 MedTeX

ADmit Therapeutics selected in the MedTeX programme organized by Barcelona Scientific Park.

http://www.pcb.ub.edu...

Apr. 25, 2018 Lab4Health

ADmit Therapeutics is one of five start ups selected to participate in the Lab4Health in the social impact accelerator Ship2B.

https://www.ship2b.org...
https://twitter.com/Ship2B...
Dec. 21, 2017 ADmit Therapeutics S.L. is created

ADmit Therapeutics has been created, acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early AD detection.

This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser